IOVA · Iovance Biotherapeutics, Inc.
$6.98
+0.46 (+7.06%)
At close · Aug 14
Market Cap
$3.16B
Shares
452.97M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Corleen Roche | Chief Financial Officer | Appointed | 2025-08-07 |
| Corleen Roche | Chief Financial Officer | Appointed | 2025-07-15 |
| Matthew W. Rosinack | interim Principal Financial Officer and Principal Accounting Officer | Appointed | 2025-07-03 |
| Jean-Marc Bellemin | Chief Financial Officer and principal financial and accounting officer | Resigned | 2025-06-13 |
| Merrill A. McPeak | member of the Board of Directors | Retired | 2024-03-29 |
| Wendy L. Yarno | director and new member of the Board | Appointed | 2023-04-24 |
| Wendy Dixon, Ph.D. | director | Appointed | 2022-06-13 |
Key facts
CIK
1425205
CUSIP
462260100
13F (30d)
277 filings
274 filers
Visit website
Investor relations